FROI now retitled PharmaRoth Labs. New name.New Ticker: ROTH. And it's a non-SEC filing dark Pinky stinky.
Same old pump and dump scam, though.
It can only be a matter of time before ROTH starts
hiring IRPs to pimp its worthless
paper all over the Internet.
Dark, dark, dark:
"FROI Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-53337
FERO INDUSTRIES, INC.
(Exact name of registrant as specified in its charter)
c/o Kane Kessler, P.C.
1350 Avenue of the Americas, New York, NY 10019
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) [ ]
Rule 12g-4(a)(2) [X]
Rule 12h-3(b)(1)(i) [ ]
Rule 12h-3(b)(1)(ii) [X]
Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or notice date: 12
Pursuant to the requirements of the Securities Exchange Act of 1934, Fero Industries, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
FERO INDUSTRIES, INC.
Date: December 31, 2012 By: Luis Manuel Ornelas Lopez
Name: Luis Manuel Ornelas Lopez
Title: President and Chief Executive Officer
Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature."
DD section maintained by Roger Wilco
|PharmaRoth Labs, Inc. |
10080 Alta Drive Suite 115
Las Vegas, NV 89145
Luis Manuel Ornelas Lopez President, CEO, COO
Barry Hall Interim CFO
OTC Pink Current Information
Pacific Stock Transfer Co.
|Shares Outstanding ||316,281,637 ||a/o Nov 19, 2014 |
|Float ||124,850,000 ||a/o Jan 22, 2014 |
|Authorized Shares ||500,000,000 ||a/o Oct 01, 2014 |
Latest Report: Sep 30, 2014 Quarterly Report
Fiscal Year End 6/30
|PharmaRoth Labs, Inc. is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon(R), an oral treatment for Type-II diabetes. Sucanon(R) is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon(R) globally. |
| || |Sucanon®...Diabetes is not curable but is treatable...enjoy life™
The increase in the total population of diabetics, may raise total U.S. sales of insulin and oral type 2 diabetes therapies to $24.4 billion, from $10.3 billion in 2008.
What is Sucanon®?:
Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
| || |
1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose 2. Sucanon® increases the binding of insulin to its receptors 3. Sucanon® increases the internalization of insulin 4. As a result, Sucanon® increases the intracellular level of insulin, which then increases the uptake of glucose.
Sucanon® is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels. Type II Diabetics produce insulin, but their cells gradually lose the ability to absorb and use insulin, to get sugar out of the blood stream. Sucanon® transports sugar out of the blood stream and into cells where it can be burned. Sucanon® particularly helps muscle cells use insulin and thus draw sugar out of the blood stream.
Sucanon® increases sensitivity to insulin which leads to decreased blood sugar levels and a reduction of a wide range of Type II Diabetes symptoms, including: weight gain, fatigue, excess thirst and excess urination. The reduction in blood sugar levels also reduces the possibility of peripheral nerve damage; the damage caused to peripheral nerves by chronic high blood sugar can ultimately lead to impotence in men and amputation of limbs in both men and women.
Farmacias del Ahorro
Fero Industries Expands Sucanon® Distribution in Mexico
Calgary, Canada - July 13, 2011 - Fero Industries, Inc. (OTCQB: FROI) (the "Company") is pleased to report that Merck S.A. de C.V. has successfully expanded Sucanon® retail distribution throughout Mexico from 900 points-of-sale to over 2,500 outlets and pharmacy chains. Sucanon® is available over-the-counter in Mexico from many well-known retailers including WalMart Supercenters, Superama, Farmacias del Ahorro, Comercial Mexicana, Farmacias Guadalajara, Soriana, Farmacias San Pablo, and Gusher Farmacias.
"Due to the excellent performance of Merck S.A. de C.V. as our business partners, Sucanon® is well positioned on the most important retail shelves throughout Mexico," said Mr. Luis M. Lopez, Chief Operating Officer of Fero Industries Inc. and President of Pharmaroth S.A., the Company's Mexican subsidiary. "This rapid expansion of distribution has placed Sucanon® and Sucanon® related marketing material in almost three times as many retail stores and should continue to boost market awareness and acceptance of Sucanon® as an over-the-counter treatment for type-2 diabetes across Mexico."
Sucanon® is approved as an over-the-counter ("OTC") remedy for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V. (Merck S.A. de C.V. is the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck KGaA.)
Commercial sales of Sucanon® began in January 2011 in Mexico. Mexico has one of the largest and fastest growing diabetic populations in the world, estimated at 15% of the total population. This indicates over 16 million diagnosed cases of diabetes, up seven fold since 1990. Diabetes is now the leading cause of death in Mexico and costs the country more than one-third of its total public health care budget annually.
|Comercial Mexicana. |
|Farmacias Guadalajara |
|Farmacias San Pablo |
|Gusher Farmacias |